ABCL-261: STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma

2021 ◽  
Vol 21 ◽  
pp. S385-S386
Author(s):  
Yana Mangasarova ◽  
Natalya Risinskaya ◽  
Yana Kozhevnikova ◽  
Julia Chabaeva ◽  
Anna Yushkova ◽  
...  
2021 ◽  
Vol 21 ◽  
pp. S242
Author(s):  
Yana Mangasarova ◽  
Natalya Risinskaya ◽  
Yana Kozhevnikova ◽  
Julia Chabaeva ◽  
Anna Yushkova ◽  
...  

2014 ◽  
Vol 11 (100) ◽  
pp. 20140785 ◽  
Author(s):  
Luz Adriana Nicasio-Collazo ◽  
Alexandra Delgado-González ◽  
Ramón Castañeda-Priego ◽  
Enrique Hernández-Lemus

DNA damage is one of the mechanisms of mutagenesis. Sequence integrity may be affected by the action of thermal changes, chemical agents, both endogenous and exogenous, and other environmental issues. Abnormally high mutation rates are referred to as genomic instability : a phenomenon closely related to the onset of cancer. Mutant genotypes may be able to confer some kind of selective advantage on subclonal cell populations, leading them to multiply until dominance in a localized tissue environment that later becomes the tumour. Cellular stress, especially that of oxidative and ionic nature, is a recognized trigger for DNA-damaging processes. A physico-chemical model has shown that high hysteresis rates in DNA denaturation curves may be indicative of dissipative processes inducing DNA damage, thus potentially leading to uncontrolled mutagenesis and genome instability. We here study selectively to what extent this phenomenon may occur by analysing the sequence length and composition effects on the thermodynamic behaviour and the presence of hysteresis in pressure-driven DNA denaturation; pronounced hysteresis in the denaturation/renaturation curves may indicate thermal susceptibility to DNA damage. In particular, we consider highly mutated regions of the genome characterized in diffuse large B-cell lymphoma on a recent whole exome next-generation sequencing effort.


2015 ◽  
Vol 21 ◽  
pp. 153-154
Author(s):  
Abhijana Karunakaran ◽  
Kadapalakere Reddy ◽  
Anshu Alok ◽  
Manav Batra ◽  
Ajay Chaudhuri ◽  
...  
Keyword(s):  
B Cell ◽  

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.


Sign in / Sign up

Export Citation Format

Share Document